Organon Expects 2028 ‘Tidal Wave’ For Biosimilars

Firm’s Opdivo And Keytruda Rivals Will Follow Denosumab And Pertuzumab In Coming Years

 
• By David Wallace
  
Amazing, perfect wave - Image
Organon CEO Kevin Ali predicts a ‘tidal wave’ of competition in 2028
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products